Bionano Genomics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bionano Genomics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 2,068% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 92% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 89% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$17For every $100 of sales, $17 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $86 tied up three years earlier.
Less money tied up than 65% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +3% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+3% / -76%In 3 years sales changed by +3% while total assets changed by -76%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-17.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+89%Cash, after subtracting all debt, equals 89% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
94%Of every $100 the company owns, $94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 69% of Healthcare companies in United States.
Tangible Net Worth Ratio
90%Of every $100 of net worth, $90 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 72% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Bionano Genomics, Inc. made a loss over the last year. Bionano Genomics, Inc. owes $0.34 for every $1 it owns. Bionano Genomics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBionano Genomics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.44The share price is 0.44 times Bionano Genomics, Inc.'s book value per share, lower than 93% of Healthcare companies in United States.
Market cap
$14 MThe total market value of all of Bionano Genomics, Inc.'s shares at today's price (share price × number of shares), smaller than 85% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$32 MWhat Bionano Genomics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.68Net worth divided by the number of shares. The share price of $1.18 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-83.6%Bionano Genomics, Inc. lost 83.6% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
Owes vs Owns
0.34×Bionano Genomics, Inc. owes $0.34 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.
Dividend yield
NoneBionano Genomics, Inc. does not currently pay a dividend.
Revenue growth
-7%Revenue fell 7% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Profit growth
LossBionano Genomics, Inc. made a loss in each of the last two years.
Profit margin
-92.6%Bionano Genomics, Inc. lost $93 for every $100 of revenue.
Interest cover
Not coveredBionano Genomics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashBionano Genomics, Inc. held $12 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bionano Genomics, Inc.: $14 M ÷ $32 M (30 Jun 2026) = 0.4.
What is Bionano Genomics, Inc.'s return on equity?
Bionano Genomics, Inc. lost 83.6% of its shareholders' money over the last year, lower than 67% of Healthcare companies in United States.
How much does Bionano Genomics, Inc. owe compared with what it owns?
Bionano Genomics, Inc. owes $0.34 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.
Does Bionano Genomics, Inc. pay a dividend?
No. Bionano Genomics, Inc. does not currently pay a dividend.
Is Bionano Genomics, Inc.'s revenue growing?
Revenue fell 7% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.